论文信息 - Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). - 字舞流文

Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

C. Porta | T. Powles | R. Motzer | E. Plimack | B. Rini | Y. Tomita | M. Grimm | B. Escudier | P. Barthélémy | F. Donskov | D. McDermott | N. Tannir | S. Tykodi | S. George | H. Hammers | M. McHenry | O. Aren | V. Neiman | A. Amin | S. S. Saggi | M. McHenry | Brian I. Rini | David McDermott | Osvaldo Rudy Aren | D. McDermott